All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 12, 2021
Home » Topics » Ocular, BioWorld

Ocular, BioWorld
%{topic} RSS Feed RSS

Close-up of eye with digital focus

Eye wouldn’t be so certain: Finding chinks in faricimab’s armor as Regeneron racks up more data

April 2, 2021
By Randy Osborne
No Comments
At the end of March, JAMA Ophthalmology’s publication of first results from the NIH-sponsored, 328-patient trial with Regeneron Pharmaceuticals Inc.’s VEGF inhibitor, Eylea (aflibercept), in non-proliferative diabetic retinopathy bolstered investor hopes for wider use. But competitors loom for the compound, first approved in November 2011 for wet age-related macular degeneration.
Read More

Lianbio inks $200M deal with Tarsus to license eye drug candidate TP-03 for greater China

March 31, 2021
By Elise Mak
No Comments
Lianbio Co. Ltd. has inked a $200 million deal with Tarsus Pharmaceuticals Inc. for greater China rights to the phase IIb/III-stage candidate, TP-03 (lotilaner ophthalmic solution, 0.25%), designed to treat Demodex blepharitis and Meibomian gland disease.
Read More
Ear illustration

Proqr procures strong phase I/II data and an FDA chat for next steps

March 24, 2021
By Lee Landenberger
No Comments
RNA therapy developer Proqr Therapeutics NV’s phase I/II study of adults with Usher syndrome and non-syndromic retinitis pigmentosa met all its key objectives, prompting the company to plan two parallel pivotal phase II/III studies that could start by year-end. The company wasted no time as it has already discussed next steps with the FDA to support the therapy’s registration “as soon as possible,” Aniz Girach, Proqr’s chief medical officer, told investors during a March 24 investor call.
Read More
Elisabet de los Pinos, CEO, Aura

Aura Biosciences readies for phase III ocular cancer program with $80M in new financing

March 22, 2021
By Michael Fitzhugh
No Comments
Aura Biosciences Inc., a company developing a virus-like drug conjugate (VDC) for the potential treatment of a type of rare ocular cancer, has closed an oversubscribed $80 million financing.
Read More

Uni-Bio and Dotbio to co-develop multispecific Dotbodies for retinal diseases

March 17, 2021
By David Ho
No Comments
HONG KONG –Uni-Bio Science Group Ltd. and Dotbio Pte. Ltd. formed a partnership to develop therapeutics for patients with retinal diseases, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and myopic choroidal neovascularization.
Read More

Azura Ophthalmics advances to registration study on positive phase II results in Meibomian gland disfunction

March 11, 2021
By Tamra Sami
No Comments
PERTH, Australia – Sydney-based Azura Ophthalmics Ltd. has moved into a registration trial following positive phase II results for lead candidate AZR-MD-001 in Meibomian gland dysfunction, the leading cause of dry eye disease.
Read More
Eye illustration

Arctic Vision closes $100M+ series B worth to move UME drug to phase III in China

March 10, 2021
By Elise Mak
No Comments
Chinese eye disease specialist Arctic Vision Biotechnology Co. Ltd. raised more than $100 million in a series B financing round. The clinical-stage company will use the funds to initiate a phase III trial for its core asset, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension), for uveitic macular edema in China this year.
Read More

Down 51%, a gray day for Graybug Vision on mixed AMD data

March 9, 2021
By Brian Orelli
No Comments
Graybug Vision Inc. reported results from the phase IIb Altissimo study testing GB-102 as a treatment for wet age-related macular degeneration (AMD) that didn't live up to expectations set by the phase I/IIa Adagio study.
Read More
Digital eye illustration

Oxular advancing once-per-year DME treatment with $37M series B

March 1, 2021
By Nuala Moran
No Comments
LONDON – Oxular Ltd. has raised $37 million in a series B, enabling the company to take OXU-001, its long-acting treatment for diabetic macular edema (DME) into phase II development later this year.
Read More

Ascend to know why bell tolls for Immunovant; lipid-hitch delay, but 1401 not Donne

Feb. 2, 2021
By Randy Osborne
No Comments
Less than a month after informing the market of a slowdown caused by pandemic-related site closures in phase II studies with neonatal Fc receptor (FcRn)-targeting IMVT-1401, Immunovant Inc. said it’s voluntarily pausing dosing with the compound in thyroid eye disease (TED) in the study called Ascend Go-2 because of a worrisome physiological signal. The New York-based firm plans to investigate and, after seeking the FDA’s go-ahead on tweaks to the program, forge onward with development.
Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 9.
  • IPO puzzle pieces

    Somalogic to merge with CM Life Sciences II SPAC, as trendy IPO path continues

    BioWorld MedTech
    Somalogic Inc. has agreed to go public via a merger with blank-check company CM Life Sciences II. Upon closing, CMLS II – a special purpose acquisition company...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for April 9.
  • Earth threatened by virus

    Global cases rise, but more weapons advance to combat COVID-19

    BioWorld
    As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing